FDAAdvisoryCommittee.com March 22, 2009 – Oncologic Drugs Advisory Committee Agenda: On March 22, 2010, during the morning session, the committee will discuss new drug application (NDA) 022-481, proposed trade name PIXUVRI (pixantrone dimaleate) injection, manufactured by Cell Therapeutics, Inc. The proposed indication (use) for this product is as a single agent treatment for patients with recurring or refractory (difficult to treat), aggressive non-Hodgkin’s lymphoma (NHL) who have received two or more prior lines of therapy.
During the afternoon session, the committee will discuss NDA 022-374, proposed trade name OMAPRO (omacetaxine mepesuccinate) for injection, manufactured by ChemGenex Pharmaceuticals. The proposed indication (use) for this product is for the treatment of adults with chronic myeloid leukemia (CML) bearing a genetic alteration known as the Bcr-Abl T315I mutation, and who have failed prior therapy with the drug imatinib
Please Click HERE for our current calendar of upcoming events
To sign up for the live webcast, go to http://fdaac.com
FDAAdvisoryCommittee.com
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment